ProLynx (San Francisco, CA), founded in 2009 by Daniel V. Santi, M.D., Ph.D., and Gary W. Ashley, Ph.D., has developed advanced linker technologies and a facile, transformative platform for controlled release of therapeutics from circulating and fixed macromolecular conjugates.

Biotechnology

Prolynx

Prolynx's headquarters in San Francisco, CA, United States

This department focuses on scientific research and innovation to develop new products and technologies.

Research and Development

The Scientific Research Team at Prolynx is dedicated to advancing innovative linker technologies and optimizing the controlled release of therapeutics. Comprising experts in various scientific domains, the team conducts cutting-edge research, develops novel drug delivery systems, and collaborates with stakeholders to translate scientific findings into practical applications for improving patient outcomes.

Scientific Research Team

This department provides expert guidance and support across various projects and initiatives.

Advisory Services

This department focuses on conducting experiments and analyses to support product development and quality assurance.

Analytical Services

The Leadership Team at Prolynx guides the strategic vision and direction of the company, leveraging their extensive expertise in biotechnology and pharmaceuticals. Comprising the President and Co-founders, they focus on fostering innovation in linker technologies and therapeutic release systems, driving research initiatives, and forming partnerships to advance the company's mission in transforming therapeutic delivery.

People (2)

Jobs (0)

Other teams

Scientific Research Team

Advisory Services

Analytical Services

Leadership Team